Unlimited HFND多策略回报追踪主动型ETF HFND 深 沪
等待开盘 05-21 09:30:00 美东时间
24.0922
+0.212
+0.89%
华盛通- 最 高24.152
- 今 开23.92
- 成交量 4.00万股
- 最 低 23.9021
- 昨 收 23.88
- 总市值 3180.17万
- 52周最高 24.50
- 市盈率 静 --
- 换手率 3.03%
- 52周最低 20.4246
- 委 比 0.00%
- 总股本 132.00万
- 历史最高 24.50
- 量 比 1.60
- 振 幅 1.05%
- 历史最低 17.475
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crinetics Pharmaceuticals Obtains European Commission Approval For PALSONIFY For The Treatment Of Acromegaly in Adults; Crinetics' First Regulatory Approval Outside Of The U.S., With First Launch Planned For Germany And Austria
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2
04-28 05:15
Bet Like A Billionaire: New ETFs Mimic Hedge Fund Moves, But For Less
Unlimited continues its effort to democratize sophisticated investment strategies that were once only accessible to those with deep pockets.
2025-07-17 00:52
Crinetics Pharmaceuticals Unveils Promising Long-Term Data for Once-Daily Oral Drug PALSONIFY in Acromegaly at ENDO 2025
Crinetics Pharmaceuticals Inc. has announced that new data from its clinical development program for the investigational drug PALSONIFYTM (paltusotine) will be presented at the Endocrine Society's Ann...
2025-07-14 05:45
Unlimited Unpacks Hedge Fund Alpha With Launch Of ETF Without High Fees, Lock-Up Features
Unlimited launches HFGM, a low-cost ETF that uses data-driven models to replicate hedge fund strategies, making them available to retail investors.
2025-04-17 02:16
